Argonaute 2 promotes myeloma angiogenesis via microRNA dysregulation

Journal of Hematology and Oncology

Volumn 7, Issue 1, 2014, Pages

  Wu, Shuang ^a   Yu, Wenjun ^a   Qu, Xiaoyan ^a   Wang, Rong ^a   Xu, Ji ^a   Zhang, Qiguo ^b   Xu, Jiaren ^a   Li, Jianyong ^a   Chen, Lijuan ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

Author keywords

Angiogenesis; Argonaute 2; let 7 family; microRNA; miR 145; miR 17 92 cluster; Myeloma

Indexed keywords

ARGONAUTE 2 PROTEIN; MICRORNA; MICRORNA 145; MICRORNA 361; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CANCER CELL LINE; CELL MIGRATION; CHICK; CHORIOALLANTOIS; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; MYELOMA; MYELOMA CELL; SUPERNATANT; TUMOR GENE; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION;

ANIMALS; ARGONAUTE PROTEINS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELLS, CULTURED; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; CULTURE MEDIA, CONDITIONED; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MICRORNAS; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTOME;

EID: 84900562611     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-7-40     Document Type: Article

References (49)

1. Multiple myeloma. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC, Lancet 2009 374 324 339 10.1016/S0140-6736(09)60221-X 19541364
2. Hematopoietic and microenvironment alterations in bone marrow from patients with multiple myeloma. Mayani H, Leuk Res 2013 37 228 229 10.1016/j.leukres.2012.11.012 23246222
3. Bone marrow microenvironment in multiple myeloma progression. Manier S, Sacco A, Leleu X, Ghobrial IM, Roccaro AM, J Biomed Biotechnol 2012 2012 157496 23093834
4. Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis. Balakumaran A, Robey PG, Fedarko N, Landgren O, Expert Rev Mol Diagn 2010 10 465 480 10.1586/erm.10.31 20465501
5. CXC chemokines in cancer angiogenesis and metastases. Keeley EC, Mehrad B, Strieter RM, Adv Cancer Res 2010 106 91 111 20399957
6. Cytokines as anti-angiogenic agents in haematological malignancies. Cocco C, Ferretti E, Airoldi I, Pistoia V, Curr Cancer Drug Targets 2011 11 997 1004 10.2174/156800911798073096 21933108
7. Biological aspects of angiogenesis in multiple myeloma. Otjacques E, Binsfeld M, Noel A, Beguin Y, Cataldo D, Caers J, Int J Hematol 2011 94 505 518 10.1007/s12185-011-0963-z 22086206
8. Clinical experience with thalidomide and lenalidomide in multiple myeloma. Moehler T, Curr Cancer Drug Targets 2012 12 372 390 10.2174/156800912800190893 22229246
9. Lenalidomide-current understanding of mechanistic properties. Tageja N, Anticancer Agents Med Chem 2011 11 315 326 10.2174/187152011795347487 21426296
10. Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. De Luisi A, Ferrucci A, Coluccia AM, Ria R, Moschetta M, de Luca E, Pieroni L, Maffia M, Urbani A, Di Pietro G, Guarini A, Ranieri G, Ditonno P, Berardi S, Caivano A, Basile A, Cascavilla N, Capalbo S, Quarta G, Dammacco F, Ribatti D, Vacca A, Clin Cancer Res 2011 17 1935 1946 10.1158/1078-0432.CCR-10-2381 21307145
11. Hypoxia and activated VEGF/receptor pathway in multiple myeloma. Giatromanolaki A, Bai M, Margaritis D, Bourantas KL, Koukourakis MI, Sivridis E, Gatter KC, Anticancer Res 2010 30 2831 2836 20683019
12. Notch1 overexpression promotes cell growth and tumor angiogenesis in myeloma. Guo D, Li C, Teng Q, Sun Z, Li Y, Zhang C, Neoplasma 2013 60 33 40 23067214
13. PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. Harvey RD, Lonial S, Future Oncol 2007 3 639 647 10.2217/14796694.3.6.639 18041916
14. MicroRNAs and cancer: past, present, and potential future. Nelson KM, Weiss GJ, Mol Cancer Ther 2008 7 3655 3660 10.1158/1535-7163.MCT-08-0586 19074842
15. MicroRNAs modulate the angiogenic properties of HUVECs. Poliseno L, Tuccoli A, Mariani L, Evangelista M, Citti L, Woods K, Mercatanti A, Hammond S, Rainaldi G, Blood 2006 108 3068 3071 10.1182/blood-2006-01-012369 16849646
16. Impaired microRNA processing causes corpus luteum insufficiency and infertility in mice. Otsuka M, Zheng M, Hayashi M, Lee JD, Yoshino O, Lin S, Han J, J Clin Invest 2008 118 1944 1954 10.1172/JCI33680 18398510 (Pubitemid 351632396)
17. Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Kuehbacher A, Urbich C, Zeiher AM, Dimmeler S, Circ Res 2007 101 59 68 10.1161/CIRCRESAHA.107.153916 17540974 (Pubitemid 47094624)
18. MiR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF. Zou C, Xu Q, Mao F, Li D, Bian C, Liu LZ, Jiang Y, Chen X, Qi Y, Zhang X, Wang X, Sun Q, Kung HF, Lin MC, Dress A, Wardle F, Jiang BH, Lai L, Cell Cycle 2012 11 2137 2145 10.4161/cc.20598 22592534
19. miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma. Chen L, Li C, Zhang R, Gao X, Qu X, Zhao M, Qiao C, Xu J, Li J, Cancer Lett 2011 309 62 70 10.1016/j.canlet.2011.05.017 21664042
20. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, Furth EE, Lee WM, Enders GH, Mendell JT, Thomas-Tikhonenko A, Nat Genet 2006 38 1060 1065 10.1038/ng1855 16878133 (Pubitemid 44325933)
21. Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. Doebele C, Bonauer A, Fischer A, Scholz A, Reiss Y, Urbich C, Hofmann WK, Zeiher AM, Dimmeler S, Blood 2010 115 4944 4950 10.1182/blood-2010-01-264812 20299512
22. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Bonauer A, Carmona G, Iwasaki M, Mione M, Koyanagi M, Fischer A, Burchfield J, Fox H, Doebele C, Ohtani K, Chavakis E, Potente M, Tjwa M, Urbich C, Zeiher AM, Dimmeler S, Science 2009 324 1710 1713 10.1126/science. 1174381 19460962
23. Transcription and processing of human microRNA precursors. Cullen BR, Mol cell 2004 16 861 865 10.1016/j.molcel.2004.12.002 15610730 (Pubitemid 40018397)
24. Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. Suarez Y, Fernandez-Hernando C, Yu J, Gerber SA, Harrison KD, Pober JS, Iruela-Arispe ML, Merkenschlager M, Sessa WC, Proc Natl Acad Sci U S A 2008 105 14082 14087 10.1073/pnas.0804597105 18779589
25. Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Suarez Y, Fernandez-Hernando C, Pober JS, Sessa WC, Circ Res 2007 100 1164 1173 10.1161/01.RES.0000265065.26744.17 17379831 (Pubitemid 46684129)
26. The Argonaute protein family. Hock J, Meister G, Genome Biol 2008 9 210 10.1186/gb-2008-9-2-210 18304383
27. Disappearance of the angiogenic potential of endothelial cells caused by Argonaute2 knockdown. Asai T, Suzuki Y, Matsushita S, Yonezawa S, Yokota J, Katanasaka Y, Ishida T, Dewa T, Kiwada H, Nango M, Oku N, Biochem Biophys Res Commun 2008 368 243 248 10.1016/j.bbrc.2008.01.074 18222171
28. [Antineovascular gene therapy by Ago2 knockdown]. Hatanaka K, Shimizu K, Asai T, Oku N, Yakugaku Zasshi 2008 128 1567 1575 10.1248/yakushi.128.1567 18981691
29. High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Zhou Y, Chen L, Barlogie B, Stephens O, Wu X, Williams DR, Cartron MA, van Rhee F, Nair B, Waheed S, Pineda-Roman M, Alsayed Y, Anaissie E, Shaughnessy JD Jr, Proc Natl Acad Sci U S A 2010 107 7904 7909 10.1073/pnas.0908441107 20385818
30. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D, Taccioli C, Zanesi N, Alder H, Hagan JP, Munker R, Volinia S, Boccadoro M, Garzon R, Palumbo A, Aqeilan RI, Croce CM, Proc Natl Acad Sci U S A 2008 105 12885 12890 10.1073/pnas.0806202105 18728182
31. MiR-15a, miR-16-1 and miR-17-92 cluster expression are linked to poor prognosis in multiple myeloma. Gao X, Zhang R, Qu X, Zhao M, Zhang S, Wu H, Jianyong L, Chen L, Leuk Res 2012 36 1505 1509 10.1016/j.leukres.2012.08.021 22959509
32. Angioarrestin: a unique angiopoietin-related protein with anti-angiogenic properties. Dhanabal M, Jeffers M, LaRochelle WJ, Lichenstein HS, Biochem Biophys Res Commun 2005 333 308 315 10.1016/j.bbrc.2005.05.134 15950186 (Pubitemid 40848293)
33. MicroRNA-145 targets vascular endothelial growth factor and inhibits invasion and metastasis of osteosarcoma cells. Fan L, Wu Q, Xing X, Wei Y, Shao Z, Acta Biochim Biophys Sin (Shanghai) 2012 44 407 414 10.1093/abbs/gms019 22472569
34. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van Rhee F, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B, Blood 2007 109 2276 2284 10.1182/blood-2006-07-038430 17105813 (Pubitemid 46425864)
35. Argonaute proteins: potential biomarkers for human colon cancer. Li L, Yu C, Gao H, Li Y, BMC Cancer 2010 10 38 10.1186/1471-2407-10-38 20146808
36. Argonaute-2 expression is regulated by epidermal growth factor receptor and mitogen-activated protein kinase signaling and correlates with a transformed phenotype in breast cancer cells. Adams BD, Claffey KP, White BA, Endocrinol 2009 150 14 23 10.1210/en.2008-0984
37. Overexpression of human Argonaute2 inhibits cell and tumor growth. Zhang X, Graves P, Zeng Y, Biochim Biophys Acta 1830 2012 2553 2561
38. Stilbene derivatives promote Ago2-dependent tumour-suppressive microRNA activity. Hagiwara K, Kosaka N, Yoshioka Y, Takahashi RU, Takeshita F, Ochiya T, Sci Rep 2012 2 314 22423322
39. The microenvironment and molecular biology of the multiple myeloma tumor. Lemaire M, Deleu S, De Bruyne E, Van Valckenborgh E, Menu E, Vanderkerken K, Adv Cancer Res 2011 110 19 42 21704227
40. Argonaute proteins at a glance. Ender C, Meister G, J Cell Sci 2010 123 1819 1823 10.1242/jcs.055210 20484662
41. miRNAs as modulators of angiogenesis. Landskroner-Eiger S, Moneke I, Sessa WC, Cold Spring Harb Perspect Med 2013 3 006643 23169571
42. Angiopoietin-related/angiopoietin-like proteins regulate angiogenesis. Oike Y, Yasunaga K, Suda T, Int J Hematol 2004 80 21 28 10.1532/IJH97.04034 15293564 (Pubitemid 38937871)
43. Expression of VEGF and its receptors by myeloma cells. Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Fonseca R, Greipp PR, Rajkumar SV, Leukemia 2003 17 2025 2031 10.1038/sj.leu.2403084 14513053 (Pubitemid 37322133)
44. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Sachdeva M, Mo YY, Cancer Res 2010 70 378 387 10.1158/0008-5472.CAN-09-2021 19996288
45. MicroRNA gene expression deregulation in human breast cancer. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM, Cancer Res 2005 65 7065 7070 10.1158/0008-5472.CAN-05-1783 16103053 (Pubitemid 41161233)
46. Reduced accumulation of specific microRNAs in colorectal neoplasia. Michael MZ, SM OC, van Holst Pellekaan NG, Young GP, James RJ, Mol Cancer Res 2003 1 882 891 14573789 (Pubitemid 37288707)
47. Hypoxia inducible factor 1alpha and hypoxia inducible factor 2alpha play distinct and functionally overlapping roles in oral squamous cell carcinoma. Zhu GQ, Tang YL, Li L, Zheng M, Jiang J, Li XY, Chen SX, Liang XH, Clin Cancer Res 2010 16 4732 4741 10.1158/1078-0432.CCR-10-1408 20807755
48. Cell-specific and hypoxia-dependent regulation of human HIF-3alpha: inhibition of the expression of HIF target genes in vascular cells. Augstein A, Poitz DM, Braun-Dullaeus RC, Strasser RH, Schmeisser A, Cell Mol Life Sci 2011 68 2627 2642 10.1007/s00018-010-0575-4 21069422
49. Angiogenic potential of the cerebrospinal fluid (CSF) of patients with high-grade gliomas measured with the chick embryo chorioallantoic membrane assay (CAM). Sinning M, Letelier R, Rosas C, Fuenzalida M, Lemus D, Biol Res 2012 45 135 138 10.4067/S0716-97602012000200005 23096357